Pulling SEC filings + quote and writing the call…

Xeris Biopharma Holdings, Inc.
Next earnings Aug 5, 2026 · consensus $0.00 EPS, $92.1M rev
Last earnings +4.1% on 2026-05-07
Revenue grew 43.7% YoY; but thin net margin (0.2%).
Xeris Biopharma Holdings, Inc. shows $292M in FY2025 revenue (+43.7% YoY), a 0.2% net margin, and 4.0% ROE.
Sources: SEC EDGAR (CIK 0001867096, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 10:04:20 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $49.6M | $110M | $164M | $203M | $292M |
| Gross profit | — | — | — | — | — |
| Operating income | -$115M | -$81.9M | -$44.0M | -$33.6M | $24.9M |
| Net income | -$123M | -$94.7M | -$62.3M | -$54.8M | $554K |
| Diluted EPS | -$1.55 | -$0.70 | -$0.45 | -$0.37 | $0.00 |
| Net margin | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 6 sales
| 2026-06-04 | Kong Garheng Director | Award | 24.2K | |
| 2026-06-04 | PERSKY MARLA Director | Award | 24.2K | |
| 2026-06-04 | HALKUFF DAWN Director | Sell | 20.0K @ $6.09 | $122K |
| 2026-06-04 | HALKUFF DAWN Director | Award | 24.2K | |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE Director | Sell | 16.0K @ $6.09 | $97.5K |
| 2026-06-04 | BORMANN-KENNEDY BARBARA-JEAN ANNE Director | Award | 24.2K | |
| 2026-06-04 | JOHNSON JOHN Director | Sell | 15.0K @ $6.09 | $91.4K |
| 2026-06-04 | JOHNSON JOHN Director | Award | 24.2K | |
| 2026-06-04 | Brady James Aloysius Director | Award | 24.2K | |
| 2026-06-03 | PERSKY MARLA Director | Sell | 15.5K @ $5.90 | $91.4K |
| 2026-06-01 | Hecht Beth See Remarks | Sell | 16.7K @ $6.06 | $101K |
| 2026-05-01 | Hecht Beth See Remarks | Sell | 16.7K @ $6.23 | $104K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.